PT - JOURNAL ARTICLE AU - Tade, Funmilayo I. AU - Sajdak, Rebecca A. AU - Gabriel, Mehdat AU - Wagner, Robert H. AU - Savir-Baruch, Bital TI - Best Practices for <sup>18</sup>F-Fluciclovine PET/CT Imaging of Recurrent Prostate Cancer: A Guide for Technologists AID - 10.2967/jnmt.119.227116 DP - 2019 Dec 01 TA - Journal of Nuclear Medicine Technology PG - 282--287 VI - 47 IP - 4 4099 - http://tech.snmjournals.org/content/47/4/282.short 4100 - http://tech.snmjournals.org/content/47/4/282.full SO - J. Nucl. Med. Technol.2019 Dec 01; 47 AB - 18F-fluciclovine is a Food and Drug Administration–approved PET tracer indicated for patients suspected to have recurrent prostate cancer based on a prostate-specific antigen rise after prior therapy. 18F-fluciclovine PET/CT is performed significantly differently from 18F-FDG PET/CT and requires special attention to patient preparation, injection technique, and imaging time. This article aims to provide nuclear medicine technologists with the best-practice guidelines for the 18F-fluciclovine PET/CT protocol.